Now Available: Final Rule for FDAAA 801 and NIH Policy on Clinical Trial Reporting
99 studies found for:    "Inflammatory breast cancer"
Show Display Options
Rank Status Study
1 Recruiting Case-Control Study of Inflammatory Breast Cancer in North Africa
Condition: Inflammatory Breast Cancer
Intervention:
2 Recruiting Efficacy and Safety of Bevacizumab in the Neodjuvant Treatment of Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer
Interventions: Biological: Bevacizumab;   Drug: Cyclophosphamide;   Drug: epirubicin hydrochloride;   Drug: fluorouracil;   Drug: Docetaxel;   Biological: Trastuzumab
3 Recruiting A Phase 2 Study of Eribulin Followed by AC as Preoperative Therapy for HER2-negative Inflammatory Breast Cancer
Conditions: Inflammatory Breast Cancer;   Human Epidermal Growth Factor 2 Negative Carcinoma of Breast
Interventions: Drug: Eribulin;   Drug: Adriamycin;   Drug: Cyclophosphamide
4 Not yet recruiting Study Of Ruxolitinib (INCB018424) With Preoperative Chemotherapy For Triple Negative Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer (IBC).
Interventions: Drug: Ruxolitinib;   Drug: Paclitaxel;   Drug: Doxorubicin;   Drug: Cyclophosphamide
5 Completed Establishing an Inflammatory Breast Cancer Registry
Condition: Inflammatory Breast Cancer
Intervention:
6 Completed Pilot Study of Inflammatory Breast Cancer in Egypt and Tunisia
Condition: Inflammatory Breast Cancer
Intervention:
7 Suspended Romidepsin and Abraxane in Treating Patients With Metastatic Inflammatory Breast Cancer
Conditions: HER2-negative Breast Cancer;   Inflammatory Breast Cancer;   Male Breast Cancer;   Recurrent Breast Cancer;   Stage IV Breast Cancer
Interventions: Drug: Romidepsin;   Drug: Abraxane
8 Completed Interest of Maintenance Chemotherapy After Induction Treatment for Inflammatory Breast Cancer
Condition: Inflammatory Breast Cancer
Interventions: Drug: Docetaxel;   Drug: Cyclophosphamide;   Drug: Epirubicin
9 Not yet recruiting Ipilimumab and Nivolumab in Treating Patients With Recurrent Stage IV HER2 Negative Inflammatory Breast Cancer
Conditions: HER2/Neu Negative;   Recurrent Inflammatory Breast Carcinoma;   Stage IV Breast Cancer;   Stage IV Inflammatory Breast Carcinoma
Interventions: Biological: Ipilimumab;   Other: Laboratory Biomarker Analysis;   Biological: Nivolumab
10 Completed Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: Carboplatin;   Drug: background treatment
11 Active, not recruiting Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto)
Conditions: Tubular Breast Cancer Stage II;   Mucinous Breast Cancer Stage II;   Breast Cancer Female NOS;   Invasive Ductal Breast Cancer;   Tubular Breast Cancer Stage III;   HER-2 Positive Breast Cancer;   Inflammatory Breast Cancer Stage IV;   Inflammatory Breast Cancer
Interventions: Drug: nab-Paclitaxel;   Drug: Paclitaxel
12 Recruiting Pilot Study of Zirconium-89 Bevacizumab Positron Emission Tomography for Imaging Angiogenesis in Patients With Inflammatory Breast Carcinoma Receiving Preoperative Chemotherapy
Condition: Inflammatory Breast Carcinoma
Interventions: Drug: 89Zr-bevacizumab;   Procedure: FDG-PET/CT;   Procedure: MRI scan;   Procedure: Tumor biopsies
13 Active, not recruiting Sunitinib Malate, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide Before Surgery in Treating Patients With Stage IIB-IIIC Breast Cancer
Conditions: Inflammatory Breast Cancer;   Male Breast Cancer;   Stage II Breast Cancer;   Stage IIIA Breast Cancer;   Stage IIIB Breast Cancer;   Stage IIIC Breast Cancer
Interventions: Drug: sunitinib malate;   Drug: paclitaxel;   Drug: doxorubicin hydrochloride;   Drug: cyclophosphamide;   Biological: filgrastim;   Procedure: therapeutic conventional surgery;   Other: laboratory biomarker analysis;   Other: flow cytometry
14 Unknown  Dose-escalation Study of Oral CX-4945
Conditions: Advanced Solid Tumors;   Breast Cancer;   Inflammatory Breast Cancer;   Castleman's Disease;   Multiple Myeloma
Intervention: Drug: CX-4945 oral formulation
15 Recruiting Inflammatory Breast Cancer (IBC) Registry
Condition: Breast Cancer
Interventions: Other: Interview;   Procedure: Blood and Tissue Collection
16 Completed Inflammatory Breast Cancer, Tumor Markers, and Factors Associated With Angiogenesis
Condition: Breast Neoplasms
Intervention:
17 Not yet recruiting A Phase II Study of Using Panitumumab/Carboplatin/Paclitaxel (PaCT) Followed by Anthracycline-Containing Regimen (AC) for New Triple-Negative Inflammatory Breast Cancer (TN-IBC)
Condition: Malignant Neoplasm of Breast
Interventions: Procedure: Breast Core Biopsy;   Drug: Paclitaxel;   Drug: Carboplatin;   Drug: Panitumumab;   Drug: Doxorubicin;   Drug: Cyclophosphamide;   Procedure: Mammogram;   Procedure: Ultrasound;   Other: Follow Up
18 Terminated
Has Results
Phase II Neoadjuvant in Inflammatory Breast Cancer
Condition: Breast Cancer
Interventions: Drug: Lapatinib;   Drug: Paclitaxel;   Drug: 5-Fluorouracil (5-FU);   Drug: Epirubicin;   Drug: Cyclophosphamide
19 Recruiting MK-3475 for Metastatic Inflammatory Breast Cancer (MIBC)
Condition: Breast Cancer
Interventions: Drug: MK-3475;   Behavioral: Follow Up/Phone Call
20 Completed TKI258 for Metastatic Inflammatory Breast Cancer Patients
Condition: Breast Cancer
Intervention: Drug: Dovitinib

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years